Last reviewed · How we verify
large protein molecule
At a glance
| Generic name | large protein molecule |
|---|---|
| Sponsor | Halozyme Therapeutics |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy (PHASE2)
- THIO Sequenced With Cemiplimab in Advanced NSCLC (PHASE2)
- A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC (PHASE3)
- Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer (PHASE2)
- NeoVax With Nivolumab in Patients With Ovarian Cancer (PHASE1)
- ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D (PHASE3)
- Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer (NA)
- Using Tumor Models to Determine Treatments (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- large protein molecule CI brief — competitive landscape report
- large protein molecule updates RSS · CI watch RSS
- Halozyme Therapeutics portfolio CI